# Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

> **NCT06176534** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Treatment
- HR Low/HER2 Negative

## Interventions

- **DRUG:** Experimental: chemotheyapy
- **DRUG:** Active Comparator: endocrine therapy

## Key facts

- **NCT ID:** NCT06176534
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-12-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176534, "Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06176534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*